Taiwan FDA registration cea87959acbe14b10bb779a7b86a88c3
Xinshu Ding Quasi-blood glucose test system
TW: 欣舒測鼎準血糖測試系統
Taiwan·Risk Class 2·APEX BIOTECHNOLOGY CORPORATION·Registered Jun 06, 2023 – Jun 06, 2028ActiveRegistration details
- Analysis ID
- cea87959acbe14b10bb779a7b86a88c3
Company information
- Manufacturer
- APEX BIOTECHNOLOGY CORPORATION
- Manufacturer Country
- Taiwan, Province of China
- Authorized Representative
- APEX BIOTECHNOLOGY CORPORATION
Product details
- Intended Use
- This product is an in vitro diagnostic medical device, which is used to quantitatively detect the blood glucose value of microvascular whole blood, venous whole blood and arterial whole blood collected from fingertips, palms and forearms, and is also suitable for neonatal microvascular whole blood. It is available for diabetic patients to use at home and for professionals.
- Product Type (Level 1)
- A Clinical chemistry and clinical toxicology
- Product Type (Level 2)
- A.1345 Glucose Test System
- Import Information
- 國產;; QMS/QSD
Dates and status
- Registration Date
- Jun 06, 2023
- Expiry Date
- Jun 06, 2028
About this record
Access comprehensive regulatory information for Xinshu Ding Quasi-blood glucose test system in Taiwan's medical device market through Pure Global AI's free database. This Risk Class 2 medical device is registered under number cea87959acbe14b10bb779a7b86a88c3 and manufactured by APEX BIOTECHNOLOGY CORPORATION. The authorized representative in Taiwan is APEX BIOTECHNOLOGY CORPORATION.
This page provides complete technical specifications, regulatory compliance details. Pure Global AI offers free access to 89,000+ Taiwan medical device registrations, helping global MedTech companies navigate Taiwan FDA regulations, identify competitors, and discover partnership opportunities efficiently.
Free DatabasePowered by Pure Global AI89,000+ Devices